Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice

Enteritis with immune checkpoint inhibitor use

David Sanders, Douglas Webber and Nazira Chatur
CMAJ October 07, 2019 191 (40) E1106; DOI: https://doi.org/10.1503/cmaj.190244
David Sanders
Division of Gastroenterology (Chatur), Department of Medicine, and Department of Pathology and Laboratory Medicine (Webber), Faculty of Medicine, Vancouver General Hospital (Sanders), University of British Columbia, Vancouver, BC
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas Webber
Division of Gastroenterology (Chatur), Department of Medicine, and Department of Pathology and Laboratory Medicine (Webber), Faculty of Medicine, Vancouver General Hospital (Sanders), University of British Columbia, Vancouver, BC
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nazira Chatur
Division of Gastroenterology (Chatur), Department of Medicine, and Department of Pathology and Laboratory Medicine (Webber), Faculty of Medicine, Vancouver General Hospital (Sanders), University of British Columbia, Vancouver, BC
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

A 43-year-old man had a completely excised melanoma with local wide excision and negative sentinel node biopsy. Local recurrence and metastatic disease (confirmed by positron emission tomography) developed in his axillary lymph nodes, liver, bone and an adrenal gland. He was started on ipilimumab and nivolumab (immune checkpoint inhibitors) by his oncologist. He presented to his oncologist about 2 weeks later with nausea, vomiting, diarrhea and weight loss. He was having up to 10 episodes per day of non-bloody diarrhea and was admitted to hospital with dehydration despite oral prednisone. He was started on methylprednisolone administered intravenously; all results were negative for cultures of his stool, examination for ova and parasites, and the presence of Clostridioides difficile.

We performed an esophagogastroduodenoscopy that showed gastric (Figure 1A; Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190244/-/DC1) and duodenal inflammation. A colonoscopy showed active terminal ileitis without colitis (Figures 1B and 1C, Appendix 1). These findings were consistent with grade 3 toxicity.1 The patient’s symptoms did not respond at 72 hours to more than 2 mg/kg of intravenous methylprednisolone. We ruled out latent tuberculosis and chronic hepatitis B virus infection before starting infliximab (5 mg/kg) in hospital. The diarrhea stopped after 1 dose, along with resolution of symptoms related to immune-mediated hepatitis and arthritis. Treatment with corticosteroids was eventually tapered off, and his symptoms completely resolved after 2 subsequent doses of infliximab.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Esophagogastroduodenoscopy images of A) gastritis with nodularity, erythema and spontaneous oozing, and B) terminal ileitis with punctate apthous ulcerations and blunting of villi in a 43-year-old man with local recurrence of melanoma and metastatic disease. C) No endoscopic evidence of colitis.

Ipilimumab is an anticytotoxic T-lymphocyte–associated antigen-4 (CTLA-4) antibody and nivolumab is a programmed cell death protein 1 (PD-1) antibody that impedes the inhibitory signalling from cancer cells to cytotoxic T cells to prevent immunoevasion.1,2 Cytotoxic T-lymphocyte–associated antigen-4 is an important receptor for regulatory T cells. Corticosteroids promote regulator T-cell activities and inhibit effector T-cell activities. In our patient, infliximab, an anti-tumour necrosis factor, was more effective than corticosteroids in halting immune-mediated gastroenteritis.3 The most common gastrointestinal immune-related toxicities with dual immune checkpoint inhibitor therapies include diarrhea (44%), hepatitis (18%) and colitis (12%); however, gastritis,4 enteritis and pancreatitis can also occur.

The differential diagnosis of checkpoint inhibitor enteritis includes cytomegalovirus, other infectious enteritides, lymphocytic enteritis, drug-induced enteropathy, inflammatory bowel disease and graft-versus-host disease.5

Footnotes

  • Competing interests: Nazira Chatur has received honoraria for presentations on immune checkpoint inhibitor–related colitis from Merck and Bristol–Myers Squibb. No other competing interests were declared.

  • This article has been peer reviewed.

  • The authors have obtained patient consent.

References

  1. ↵
    1. Brahmer JR,
    2. Lacchetti C,
    3. Schneider BJ,
    4. et al.
    National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36:1714–68.
    OpenUrl
  2. ↵
    1. Esfahani K,
    2. Meti N,
    3. Miller WH Jr.,
    4. et al
    . Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ 2019;191:E40–6.
    OpenUrlFREE Full Text
  3. ↵
    1. Soularue E,
    2. Lepage P,
    3. Colombel JF,
    4. et al
    . Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056–67.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Yip RHL,
    2. Lee LH,
    3. Schaeffer DF,
    4. et al
    . Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Melanoma Res 2018;28:645–7.
    OpenUrl
  5. ↵
    1. Karamchandani DM,
    2. Chetty R
    . Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective. J Clin Pathol 2018;71:665–71.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 191 (40)
CMAJ
Vol. 191, Issue 40
7 Oct 2019
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Enteritis with immune checkpoint inhibitor use
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Enteritis with immune checkpoint inhibitor use
David Sanders, Douglas Webber, Nazira Chatur
CMAJ Oct 2019, 191 (40) E1106; DOI: 10.1503/cmaj.190244

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Enteritis with immune checkpoint inhibitor use
David Sanders, Douglas Webber, Nazira Chatur
CMAJ Oct 2019, 191 (40) E1106; DOI: 10.1503/cmaj.190244
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

Collections

  • Article Types
    • Clinical Images
  • Topics
    • Cancer & oncology
    • Drugs: immunologic
    • Gastroenterology
    • Immunology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire